BACKGROUND: While studies have compared the safety and efficacy of starter insulin regimens in type 2 diabetes, none have evaluated regimen durability (length of time a patient can maintain glycemic control) or the safety and efficacy of subsequent intensification regimens in a large, multinational cohort. METHODS: The DURABLE (Assessing the DURAbility of Basal vs Lispro Mix 75/25 Insulin Efficacy) trial will compare the ability of glargine once daily vs lispro mix 75/25 (75% insulin lispro protamine suspension, 25% lispro) twice daily added to oral antihyperglycemic agents to achieve and maintain hemoglobin A1c (HbA1c) goals. This randomized, open label, parallel study will enroll over 2000 insulin-naïve patients with type 2 diabetes from 11 countries, ages 30 to 80, with HbA1c >7.0% on at least two oral antihyperglycemic agents. At the completion of the 6-month initiation phase, safety and efficacy of the two regimens will be compared. Patients who achieve an HbA1c < or =7.0% at 6 months will continue into the 24-month maintenance phase to evaluate durability. In a substudy, patients not achieving HbA1c < or =7.0% at 6 months may be randomized to one of two intensification comparisons: patients previously on glargine will receive lispro mix 75/25 twice daily or basal/bolus therapy (glargine + thrice-daily mealtime lispro) and patients previously on lispro mix 75/25 will receive lispro mix 50/50 (50% insulin lispro protamine suspension, 50% lispro) thrice daily or basal/bolus therapy. RESULTS: Upon completion, this trial will provide new information about starter insulin durability, defined as the length of time patients can maintain HbA1c control (HbA1c < or =7.0%, or >7.0% but with an increase of <0.4% from the most recent HbA1c < or =7.0%). Additionally, the study will provide comparative data on HbA1c, blood glucose profiles, 1,5-anhydroglucitol, hypoglycemic episodes, weight change, and insulin dose for starter insulin regimens following 6 and 24 months of treatment, as well as intensified insulin via the 6-month substudy. CONCLUSION: This trial aims to broaden clinicians' understanding of the ability of starter insulin and insulin intensification regimens to achieve and maintain glycemic control in patients with type 2 diabetes.
RCT Entities:
BACKGROUND: While studies have compared the safety and efficacy of starter insulin regimens in type 2 diabetes, none have evaluated regimen durability (length of time a patient can maintain glycemic control) or the safety and efficacy of subsequent intensification regimens in a large, multinational cohort. METHODS: The DURABLE (Assessing the DURAbility of Basal vs Lispro Mix 75/25 Insulin Efficacy) trial will compare the ability of glargine once daily vs lispro mix 75/25 (75% insulinlispro protamine suspension, 25% lispro) twice daily added to oral antihyperglycemic agents to achieve and maintain hemoglobin A1c (HbA1c) goals. This randomized, open label, parallel study will enroll over 2000 insulin-naïve patients with type 2 diabetes from 11 countries, ages 30 to 80, with HbA1c >7.0% on at least two oral antihyperglycemic agents. At the completion of the 6-month initiation phase, safety and efficacy of the two regimens will be compared. Patients who achieve an HbA1c < or =7.0% at 6 months will continue into the 24-month maintenance phase to evaluate durability. In a substudy, patients not achieving HbA1c < or =7.0% at 6 months may be randomized to one of two intensification comparisons: patients previously on glargine will receive lispro mix 75/25 twice daily or basal/bolus therapy (glargine + thrice-daily mealtime lispro) and patients previously on lispro mix 75/25 will receive lispro mix 50/50 (50% insulinlispro protamine suspension, 50% lispro) thrice daily or basal/bolus therapy. RESULTS: Upon completion, this trial will provide new information about starter insulin durability, defined as the length of time patients can maintain HbA1c control (HbA1c < or =7.0%, or >7.0% but with an increase of <0.4% from the most recent HbA1c < or =7.0%). Additionally, the study will provide comparative data on HbA1c, blood glucose profiles, 1,5-anhydroglucitol, hypoglycemic episodes, weight change, and insulin dose for starter insulin regimens following 6 and 24 months of treatment, as well as intensified insulin via the 6-month substudy. CONCLUSION: This trial aims to broaden clinicians' understanding of the ability of starter insulin and insulin intensification regimens to achieve and maintain glycemic control in patients with type 2 diabetes.
Authors: R J Ligthelm; U Mouritzen; H Lynggaard; M Landin-Olsson; C Fox; C le Devehat; E Romero; A Liebl Journal: Exp Clin Endocrinol Diabetes Date: 2006-10 Impact factor: 2.949
Authors: Hans U Janka; Gerd Plewe; Matthew C Riddle; Christine Kliebe-Frisch; Matthias A Schweitzer; Hannele Yki-Järvinen Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112
Authors: Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112
Authors: Rury R Holman; Kerensa I Thorne; Andrew J Farmer; Melanie J Davies; Joanne F Keenan; Sanjoy Paul; Jonathan C Levy Journal: N Engl J Med Date: 2007-09-21 Impact factor: 91.245
Authors: Dana S Hardin; Rachelle D Rohwer; Bradley H Curtis; Anthony Zagar; Lei Chen; Kristina S Boye; Honghua H Jiang; Ilya A Lipkovich Journal: J Diabetes Sci Technol Date: 2013-03-01
Authors: John B Buse; Bruce H R Wolffenbuttel; William H Herman; Stephen Hippler; Sherry A Martin; Honghua H Jiang; Sylvia K Shenouda; Jessie L Fahrbach Journal: Diabetes Care Date: 2011-02 Impact factor: 19.112
Authors: John B Buse; Bruce H R Wolffenbuttel; William H Herman; Natalie K Shemonsky; Honghua H Jiang; Jessie L Fahrbach; Jamie L Scism-Bacon; Sherry A Martin Journal: Diabetes Care Date: 2009-03-31 Impact factor: 19.112
Authors: Bruce H R Wolffenbuttel; William H Herman; Jorge L Gross; Mala Dharmalingam; Honghua H Jiang; Dana S Hardin Journal: Diabetes Care Date: 2013-06-11 Impact factor: 19.112